Posted by kinasepro on July 18, 2007
Pfizer’s Jak3 inhibitor CP-690,550 was described earlier listed as Ph ii-iii. For some reason that was changed, and all of its furthest advanced trials are Phase 2.
This entry was posted on July 18, 2007 at 10:36 pm and is filed under JAK, Phase III.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
These are only current trials, and it looks like for alternate indications. If anything, this seems to be signalling the health of this molecule. Lots of Phase 2’s cost lots of money.
The phase of development for a drug cannnot be disentangled from its indication. Pretty common for something to be in Ph. 3 for one indication, Ph. 2a for another, already approved for a third.
Fill in your details below or click an icon to log in:
You are commenting using your WordPress.com account. ( Log Out / Change )
You are commenting using your Twitter account. ( Log Out / Change )
You are commenting using your Facebook account. ( Log Out / Change )
You are commenting using your Google+ account. ( Log Out / Change )
Connecting to %s
Notify me of new comments via email.